Latest Insider Transactions at Pliant Therapeutics, Inc. (PLRX)
This section provides a real-time view of insider transactions for Pliant Therapeutics, Inc. (PLRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PLIANT THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PLIANT THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,319
-5.47%
|
$135,509
$11.56 P/Share
|
|
Jul 10
2024
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,900
-4.17%
|
$108,900
$11.56 P/Share
|
|
Jul 10
2024
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,911
-3.72%
|
$120,021
$11.56 P/Share
|
|
Jul 10
2024
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
38,710
-7.42%
|
$425,810
$11.56 P/Share
|
|
Jul 10
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
7,656
-7.53%
|
$84,216
$11.56 P/Share
|
|
Jul 09
2024
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,063
+9.65%
|
-
|
|
Jul 09
2024
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,337
+7.53%
|
-
|
|
Jul 09
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,313
+6.78%
|
-
|
|
Jul 09
2024
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,625
+12.66%
|
-
|
|
Jul 09
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
14,954
+12.82%
|
-
|
|
May 02
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+7.17%
|
$42,000
$2.08 P/Share
|
|
Jan 23
2024
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
128,150
+22.38%
|
-
|
|
Jan 23
2024
|
Lily Cheung Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+49.25%
|
-
|
|
Jan 23
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,250
+18.11%
|
-
|
|
Jan 23
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+26.64%
|
-
|
|
Jan 23
2024
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+12.7%
|
-
|
|
Jan 23
2024
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+17.67%
|
-
|
|
Jan 17
2024
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,781
-4.79%
|
$166,277
$17.23 P/Share
|
|
Jan 17
2024
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,295
-6.16%
|
$175,015
$17.23 P/Share
|
|
Jan 17
2024
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
25,721
-7.52%
|
$437,257
$17.23 P/Share
|
|
Jan 17
2024
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,786
-5.02%
|
$166,362
$17.23 P/Share
|
|
Jan 17
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
5,197
-8.6%
|
$88,349
$17.23 P/Share
|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
20,050
-9.33%
|
$401,000
$20.01 P/Share
|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,791
+3.93%
|
$17,582
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Open market or private sale
|
Direct |
1,800
+0.87%
|
$36,000
$20.0 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+0.86%
|
$3,600
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,069
-5.96%
|
$261,380
$20.0 P/Share
|
|
Jul 20
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,755
-7.29%
|
$80,835
$17.55 P/Share
|
|
Jul 17
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
12,778
-16.39%
|
$230,004
$18.01 P/Share
|
|
Jul 17
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,937
-7.56%
|
$322,866
$18.01 P/Share
|
|
Jul 17
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,321
-11.78%
|
$401,778
$18.01 P/Share
|
|
Jul 17
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
70,150
-17.02%
|
$1,262,700
$18.01 P/Share
|
|
Jul 17
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,771
-8.84%
|
$355,878
$18.01 P/Share
|
|
Jul 14
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
27,187
+25.85%
|
-
|
|
Jul 14
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,156
+12.91%
|
-
|
|
Jul 14
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+18.75%
|
-
|
|
Jul 14
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,750
+14.76%
|
-
|
|
Jul 14
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
137,500
+25.01%
|
-
|
|
Jun 13
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,750
+14.25%
|
$61,500
$2.08 P/Share
|
|
Jun 09
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,800
+3.62%
|
$11,600
$2.08 P/Share
|
|
Apr 03
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
2,877
-2.69%
|
$77,679
$27.1 P/Share
|
|
Mar 30
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,874
-8.33%
|
$126,724
$26.52 P/Share
|
|
Mar 30
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,245
-7.16%
|
$292,370
$26.52 P/Share
|
|
Mar 30
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,036
-4.28%
|
$234,936
$26.52 P/Share
|
|
Mar 30
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
35,339
-11.4%
|
$918,814
$26.52 P/Share
|
|
Mar 30
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,960
-6.29%
|
$258,960
$26.52 P/Share
|
|
Mar 29
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
13,593
+18.84%
|
-
|
|
Mar 29
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,578
+7.69%
|
-
|
|
Mar 29
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,874
+12.23%
|
-
|
|
Mar 29
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,375
+10.9%
|
-
|